Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTkIMA: Intermittent TKI Dosing in Elderly CML
NCT02326311Phase 3Completed
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Jun 2015
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of imatinib, nilotinib, dasatinib in chronic myeloid leukemia (CML), sponsored by ASST Spedali Civili di Brescia. Started Jun 2015; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02326311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02326311.